The Gynecologic Oncology Fellowship Training Program, initiated in the 1950s by Dr. Felix Rutledge, is now the largest training program for gynecologic oncologists in the world. The goal is to train fellows to become academic gynecologic oncologists who are highly skilled, knowledgeable surgeons capable of establishing new academic gynecologic oncology programs at other teaching institutions.
To address the national shortage of academic gynecologic oncologists, the Department of Gynecologic Oncology has dedicated its T32 training program to cultivating outstanding academic Gynecologic Oncologists – both clinician investigators and physician-scientists. Our program provides opportunities in a broad range of research training disciplines including, but not limited to, cancer biology, molecular therapeutics, tumor immunology, health disparities, epidemiology, health services research, and clinical trial design/implementation. This versatility in academic training increases the likelihood of obtaining an academic position upon completion of training.
Our program was continuously accredited by the American Board of Obstetrics and Gynecology (ABOG) since the inception of subspecialty certification in 1973, until 2017 when ABOG discontinued accreditation of all gynecologic oncology programs and they were transitioned to ACGME accreditation. Our program is currently ACGME accredited (#2254822001). There are three new fellow positions per year, with a total of 12 fellows in the program at any one time.
The curriculum includes 24 months of research followed by 24 months of clinical training in gynecologic oncology. The research period permits fellows to pursue interests in either laboratory or clinical research with no routine patient responsibilities. Additionally, each fellow is required to complete a core of two courses and earn an M.S. degree or an M.P.H. degree at the UT Graduate School of Biomedical Sciences or the UT School of Public Health, respectively.
Upon completion of the two-year research period, the fellows begin an in-depth clinical training program. The clinical fellow is involved in all aspects of the patient’s care: surgery, chemotherapy, radiation therapy, intensive care, and terminal care.
Clinical training is further emphasized in the outpatient clinics where fellows are responsible for both new patient evaluations and follow-up surveillance. Gynecologic Oncology fellows are actively trained in the techniques of chemotherapeutic and biological agents used to treat gynecologic malignancies and learn treatment planning, dosing, and methods of administering a variety of agents. The practical experience is augmented with a comprehensive didactic program.
Upon satisfactory completion of the four-year fellowship program, the fellow is eligible to take the written and oral examinations of the American Board of Obstetrics and Gynecology for Board Certification in gynecologic oncology.
Eligible applicants will have completed a four-year residency program in obstetrics and gynecology accredited by the Accreditation Council for Graduate Medical Education (ACGME) in the U.S., or a five-year residency program in Canada accredited by the Royal College of Physicians and Surgeons of Canada, and are eligible to take the American Board of Obstetrics and Gynecology written examination.
Each applicant is reviewed by an Admissions Committee. Top applicants, chosen on the basis of their credentials and letters of recommendation, are invited to Houston for a formal interview.
Interviews take place over a full day and include participation of the staff. Applicants have the opportunity to tour the facility and to meet current fellows. The final selection of fellows is made in a series of joint meetings of all staff members. The selection process is administered through the National Residency Matching Program. The salary and fringe benefits are competitive.
Our deadline for a position beginning July 1, 2019, has passed.
The deadline for submission of applications for the 2020 Gynecologic Oncology Fellowship is April 1, 2019, for a position beginning July 1, 2020.
We will accept applications through the Electronic Residency Application System (ERAS).
The University of Texas MD Anderson Cancer Center
Gynecologic Oncology Fellowship
Accreditation Number: X380000036
In addition to the ERAS application, your completed application package must include:
- Three letters of recommendation (one from a program director) addressed to "Dear Program Director"
- Personal statement
- Official transcript from each medical school attended
- USMLE transcript including all attempts
- Recent photograph
- CREOG scores - please email to email@example.com
Additional Documents for Foreign Medical School Applicants
Note: Documents in a language other than English must be submitted with a certified translation.
- Transcript of all college education
- ECFMG certificate
Additional documentation may be required before a candidate can be appointed.
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
1155 Pressler Dr.
Houston, TX 77030
MD Anderson Cancer Center is committed to encouraging good health and staying true to our mission to end cancer. If you are applying for a GME fellowship or residency program starting on or after July 1, 2016, please be advised that MD Anderson will have instituted a tobacco-free hiring process as part of its efforts to achieve these goals. If you are offered an appointment, you will be subject to a Pre-Employment Drug Screen for tobacco compounds in compliance with applicable state laws. If you do not pass the urine drug screening which includes testing for tobacco compounds, you CANNOT be appointed at MD Anderson. Should you fail to meet this contingency, MD Anderson will withdraw your offer of appointment for the academic year. You may reapply for the following academic year, but there are no guarantees that you will be offered a position as many of our programs are already filled for several years out.